

## INTERIM FORMULARY UPDATE

The following recommendations, made at the October 30, 2015 meeting of the Executive Formulary Committee, are approved:

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on New Drug Applications:

| Generic Name    | Brand Name | Dosage Form | Classification                            |
|-----------------|------------|-------------|---|
| Insulin detemir | Levemir®   | 10 ml Vial  | Antidiabetic Agent<br><b>Reserve Drug</b> |

**Insulin detemir (Levemir®) Reserve Criteria: for those that are unable to tolerate insulin glargine (Lantus®).**

Other **Recommendation(s)/addition(s)/revisions(s)** to the tables listed in the DADS/DSHS Drug Formulary

- Change moxifloxacin ophthalmic to Reserve Drug. Reserve Criteria: for bacterial conjunctivitis where MRSA or gram negative microorganisms is identified or suspected.
- Delete the following trade names from the generic listings:
  - Unipen® from nafcillin
  - Ancef® from cefazolin
  - Achromycin® and Panmycin® from tetracycline
  - Amikin® from amikacin
  - Garamycin® from gentamicin
  - Mycifradin® from neomycin
  - Nebcin® from tobramycin
  - Seromycin® from cycloserine
  - Co-Trimoxazole® and Septra® from sulfamethoxazole-trimethoprim

- Add the following to the Formulary

| Generic Name                                    | Brand Name                 | Dosage forms to be added  |
|---|----------------------------|---|
| Mesalamine dr                                   | Asacol®, Pentasa®, Rowasa® | Tablet, delayed release: 800 mg   |
| Penicillin G Benzathine – Penicillin G Procaine | Bicillin C-R®              | Penicillin G Benzathine 600,000 units– Penicillin G Procaine 600,000 units/2 ml |

- Delete the following antibiotic products from the Formulary due to lack of availability:

| Generic Name            | Brand Name        | Dosage forms to be deleted   | Dosage forms still available   |
|-------------------------|-------------------|--|--|
| Amoxicillin             | Amoxil®, Polymox® | Powder for oral suspension: 50 mg/ml   | Capsule: 250 mg, 500 mg<br>Powder for oral suspension: 125 mg/5 ml, 250 mg/5 ml<br>Tablet: 500 mg, 875 mg<br>Tablet, chewable: 125 mg, 250 mg  |
| Amoxicillin-Clavulanate | Augmentin®        | Tablet: 200 mg (contains clavulanate 28.5 mg), 400 mg (contains clavulanate 57 mg) | Suspension, oral: 400 mg (contains clavulanate 57 mg) per 5 ml, 600 mg (contains clavulanate 42.9 mg) per 5 ml<br>Tablet: 250 mg (contains clavulanate 125 mg), 500 mg (contains clavulanate 125 mg), 875 mg (contains clavulanate 125 mg)<br>Tablet, chewable: 125 mg (contains clavulanate |

| Generic Name   | Brand Name                 | Dosage forms to be deleted  | Dosage forms still available  |
|--|----------------------------|---|---|
|  |                            |   | 31.25 mg), 250 mg<br>(contains clavulanate<br>62.5 mg)<br>Tablet, extended release:<br>1,000 mg (contains<br>clavulanate 62.5 mg)   |
| Nafcillin  | Unipen®                    | Capsule: 250 mg<br>Powder for injection: 4 g<br>Solution: 250 mg/5 ml<br>Tablet: 500 mg | Powder for injection:<br>500 mg, 1 g, 2 g, 10 g   |
| Penicillin G<br>Benzathine                               | Bicillin L-A®              | Injection: 300,000 units/ml   | Injection: 600,000 units/ml   |
| Penicillin G<br>Benzathine –<br>Penicillin G<br>Procaine | Bicillin C-R®              | Penicillin G Benzathine<br>150,000 units –<br>Penicillin G Procaine<br>150,000 units    | Penicillin G Benzathine<br>900,000 units –<br>Penicillin G Procaine<br>300,000 units  |
| Penicillin G<br>Procaine                                 | Wycillin®                  | Injection (suspension):<br>300,000 units/ml,<br>500,000 units/ml                        | Injection (suspension):<br>600,000 units/ml   |
| Penicillin V<br>Potassium                                | Pen-Vee K®,<br>V-Cillin K® | Tablet: 125 mg  | Powder for oral solution:<br>125 mg/5 ml,<br>250 mg/5 ml<br>Tablet: 250 mg, 500 mg  |
| Cefazolin  | Kefzol®, Ancef®            | Powder for injection:<br>250 mg   | Injection: 500 mg, 1 g<br>Powder for injection:<br>500 mg, 1 g, 5 g, 10 g,<br>20 g  |
| Cephalexin   | Keflex                     | Powder for oral suspension:<br>100 mg/ml<br>Tablet: 1 g                                 | Capsule: 250 mg, 500 mg<br>Powder for oral suspension:<br>125 mg/5 ml,<br>250 mg/5 ml<br>Tablet: 250 mg, 500 mg   |
| Azithromycin   | Zithromax®                 | Powder for oral solution:<br>400 mg/5 ml  | Powder for oral solution:<br>200 mg/5 ml<br>Tablet: 250 mg, 500 mg,<br>600 mg   |
| Tetracycline   |                            | Capsule: 100 mg<br>Suspension, oral<br>125 mg/5 ml<br>Tablet: 250 mg, 500 mg            | Capsule: 250 mg, 500 mg   |
| Gentamicin   |                            | Infusion, premixed in<br>D5W: 60 mg, 80 mg,<br>100 mg                                   | Infusion, premixed in NS:<br>40 mg, 60 mg, 80 mg,<br>90 mg, 100 mg, 120 mg<br>Injection: 10 mg/ml,<br>40 mg/ml<br>Injection, intrathecal<br>(preservative free):<br>2 mg/ml |
| Vancomycin   | Vancocin®                  | Powder for oral solution:<br>1 g, 10 g<br>Powder for injection: 2 g                     | Capsule: 125 mg, 250 mg<br>Powder for injection:<br>500 mg, 1 g, 5 g, 10 g  |
| Griseofulvin   | Fulvicin®                  | Microsize:<br>Capsule: 125 mg, 500 mg<br>Tablet: 250 mg                                 | Microsize<br>Suspension, oral:<br>125 mg/5 ml with 0.2%<br>alcohol  |

| Generic Name   | Brand Name    | Dosage forms to be deleted  | Dosage forms still available  |
|----------------|---------------|---|---|
|                |               | Ultramicrosize:<br>Tablet: 165 mg, 330 mg   | Tablet: 500 mg<br><br>Ultramicrosize:<br>Tablet: 125 mg, 250 mg   |
| Nystatin       | Mycostatin®   | Powder for oral suspension:<br>50 million units,<br>1 billion units, 2 billion<br>units, 5 billion units<br>Troche: 200,000 units | Suspension, oral:<br>100,000 units/ml<br>Tablet, oral: 500,000 units  |
| Isoniazid      |               | Tablet: 50 mg   | Injection: 100 mg/ml<br>Syrup: 50 mg/5 ml<br>Tablet: 100 mg, 300 mg   |
| Thiabendazole  | Mintezol      | Suspension, oral:<br>500 mg/5 ml<br>Tablet, chewable: 500 mg  | None  |
| Nitrofurantoin | Macrochantin® | Capsule: 50 mg, 100 mg<br>Capsule, extended release:<br>100 mg  | Capsule, macrocrystal:<br>25 mg, 50 mg 100 mg<br>Capsule, macrocrystal/<br>monohydrate: 100 mg<br>Suspension, oral:<br>25 mg/5 ml |

For the erythromycin products it was recommended that the following products be deleted:

| Generic Name                   | Brand Name                                      | Dosage forms to be deleted   | *Dosage forms still available  |
|--------------------------------|---|--|--|
| Erythromycin base              | Eryc®, E-Mycin®,<br>Ery-Tab®, E-<br>Base®, PCE® | Tablet, enteric coated:<br>250 mg, 333 mg, 500<br>mg<br>Tablet, polymer coated<br>particles: 333 mg,<br>500 mg | Capsule, delayed release:<br>250 mg<br>Tablet, film coated:<br>250 mg, 500 mg  |
| Erythromycin<br>ethylsuccinate | EryPed®, EES®                                   | Suspension, oral (drops):<br>100 mg/2.5 ml<br>Tablet, chewable: 200<br>mg                                      | Granules/Powder for oral<br>suspension:<br>200 mg/5 ml,<br>400 mg/5 ml<br>Suspension, oral:<br>200 mg/5 ml,<br>400 mg/5 ml<br>Tablet: 400 mg |

\* Moved to gastrointestinal section

- Remove from the Infectious Disease Agents and move to the gastrointestinal section:
  - Erythromycin base:
    - Capsule, delayed release: 250 mg
    - Tablet, film coated: 250 mg, 500 mg
  - Erythromycin ethylsuccinate:
    - Granules/powder for oral suspension: 200 mg/5 ml, 400 mg/5 ml
    - Suspension, oral: 200 mg/5 ml, 400 mg/5 ml
    - Tablet: 400 mg
- Add trade names Grifulvin V® and Gris-Peg® to griseofulvin

- Add treacator to ethionamide to Antituberal Section
- Remove amantadine (Symmetrel®) from the antiviral section.Keep in the Antiparkinson Agents section.
- Remove the trade name Nolvadex® from the listing as the trade name product is no longer available
- Add the following statement to the Antineoplastic Agents section:
  - All commercially available oncologic agents prescribed by a field specialist are considered to be on formulary

Updated the Antipsychotic Dosing Table as follows:

- Add the following antipsychotic entries
  - Aripiprazole lauroxil (Aristada®) – Non-Formulary; Adult dose 882 mg q 28 days
  - Brexpiprazole (Rexulti®) – Non-Formulary, Adult dose 4 mg
  - Cariprazine (Vraylar®) – Non-Formulary, Adult dose 6 mg
  - Paliperidone palmitate (Invega® Trinza™) – Non-Formulary; 819 mg q 3 month
- Add the antipsychotic plasma concentration table from the July 2015 meeting minutes for those antipsychotics that are available in the U.S. Remove any reference to plasma levels currently listed in table.

| Drug         | Therapeutic reference range/<br>Recommended drug concentration |
|--------------|--|
| Clozapine    | 350 – 600 ng/ml  |
| Fluphenazine | 1 – 10 ng/ml   |
| Haloperidol  | 1 – 10 ng/ml   |
| Olanzapine   | 20 – 80 ng/ml  |
| Perphenazine | 0.6 – 2.4 ng/ml  |
| Thioridazine | 100 – 200 ng/ml  |

Approved:

***Ann Richards***

Ann Richards, Pharm., D., BCPP  
 Pharmacy Services Director  
 San Antonio State Hospital